



(51) International Patent Classification:  
C12Q 1/6806 (2018.01)

(21) International Application Number:  
PCT/US2019/054843

(22) International Filing Date:  
04 October 2019 (04.10.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
62/741,466 04 October 2018 (04.10.2018) US  
62/832,560 11 April 2019 (11.04.2019) US

(71) Applicant: **ARC BIO, LLC** [US/US]; 10 Canal Park, Suite 201, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **HARNESS, Eric**; 920 Tamarack Lane, Apt 7, Sunnyvale, California 94086 (US). **NAGESH, Vaishnavi**; c/o Arc Bio, LLC, 10 Canal Park, Suite 201, Cambridge, Massachusetts 02141 (US). **BENTLEY, Lloyd Gordon**; c/o Arc Bio, LLC, 10 Canal Park, Suite 201, Cambridge, Massachusetts 02141 (US). **CARPENTER, Meredith L.**; 170 10th Avenue, San Mateo, California 94401 (US).


(74) Agent: **CANDE, Jessica D.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NORMALIZATION CONTROLS FOR MANAGING LOW SAMPLE INPUTS IN NEXT GENERATION SEQUENCING

FIG. 13



(57) Abstract: The disclosure provides compositions and methods for the quantification of a target nucleic acid sequence or sequences in a sample using next generation sequencing. The methods of the disclosure can be used to determine titer of one or more target organisms in a sample.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*